Historically, heart tissue has been perceived as a largely non-regenerative tissue that cannot recover adequately from injury. Heart attacks and heart failure result in the loss of heart muscle cells, significantly diminishing cardiac function. This revolutionary study, led by Dr. Hina Chaudhry and her team from the Icahn School of Medicine at Mount Sinai, provides compelling evidence suggesting that even mature human heart cells may harbor the intrinsic ability to regenerate when prompted under the right circumstances.

The research builds upon Dr. Chaudhry’s earlier pioneering work in 2014, where her team established the first-ever regeneration of a large mammalian heart model after injury through the reactivation of CCNA2. This previous research set the foundation for establishing that the regeneration of heart tissue could be achieved in mammals closely resembling humans. The new findings represent not only a continuation of this research but an essential bridge toward therapeutic applications in human populations.

Rather than exclusively treating symptoms of heart disease, this study represents a paradigm shift: it suggests that we could enable the heart to heal itself. With heart disease being the leading cause of mortality globally, Dr. Chaudhry’s work underscores a critical turning point in our understanding of cardiac biology. By taking advantage of the body’s innate regenerative capabilities, doctors may one day be able to facilitate healing processes that maximize recovery after cardiac events.

The researchers employed a sophisticated method, utilizing a replication-deficient human-compatible virus to deliver the CCNA2 gene to cultured human heart muscle cells obtained from healthy human donors. A keen analysis using time-lapse imaging revealed that heart cells treated with Cyclin A2 not only divided successfully but also maintained their essential structural integrity and functionality.

This study investigated heart cells from donors of varying ages, specifically examining samples from individuals aged 21, 41, and 55. Remarkably, stimulation with the CCNA2 therapy prompted a successful cell division response in the cells from the older donors, while the younger donor cells did not exhibit the same response. This observation aligns with previous research suggesting that younger hearts inherently possess greater regenerative potential, able to divide autonomously without external stimulation.

The essential takeaway from this research is that the produced daughter cells, resulting from the induced cell division, retained their normal calcium homeostasis and structural proteins. This finding is paramount as it indicates that the reawakening of CCNA2 does not render these cells immature or induce pathological changes like hypertrophy commonly seen in heart disease. Significantly, the work demonstrates that CCNA2 can temporarily “turn back the clock,” activating specific growth genes to facilitate division and repair.

Dr. Chaudhry has articulated the repercussions of this research, stating that it encapsulates nearly two decades of endeavor toward redefining cardiac regeneration. She envisions a therapy that may empower the heart’s innate healing mechanisms following a heart attack or during heart failure, potentially reducing dependency on transplants or mechanical aid devices.

In moving forward, the research team intends to pursue FDA approval for initiating clinical trials of the CCNA2 therapy in patients suffering from heart disease. This critical next stage involves ensuring that the promising results observed in vitro translate effectively into vivo applications in human subjects.

This essential advancement was made possible by funding from significant entities like the National Institutes of Health and the New York Stem Cell Board, emphasizing the collaborative efforts in pushing the frontiers of science. The implications of this research are profound, as it paints a hopeful picture of cardiac treatment strategies aimed at repairing rather than merely managing heart disease.

In conclusion, this study heralds a new epoch in the realm of cardiology. By reviving the innate regenerative capabilities of heart cells through the reactivation of Cyclin A2, the potential trajectory of heart disease management could transform drastically. The outcomes could shape a future where patients are not only treated but can regain functional heart cell populations capable of sustaining their cardiac health. Researchers continue to investigate this exciting new frontier, as it holds incredible promise for reimagining heart health on both individual and societal levels.

Subject of Research: Cells
Article Title: Cyclin A2 Induces Cytokinesis in Human Adult Cardiomyocytes and Drives Reprogramming in Mice
News Publication Date: 3-Nov-2025
Web References: [Link to Article]
References: [Link to Previous Studies]
Image Credits: Mount Sinai Health System

Keywords

This third round of funding marks a strategic pivot in the study of bipolar disorder, as all recipient teams are committed to employing advanced neuromodulation techniques—a set of precise interventions designed to alter neural circuit functions with a view to understanding and potentially recalibrating dysfunctional brain networks implicated in mood dysregulation. Each team stands to receive up to $4.5 million over three years, underscoring BD²’s commitment to sustained, high-impact research that bridges clinical insights with foundational neuroscience. The aim is clear: to unravel the dynamic connectivity and neural circuit disruptions that underlie bipolar disorder’s hallmark symptoms, thereby catalyzing the development of more targeted, effective interventions.

Dr. Cara Altimus, PhD, Managing Director of BD², emphasized the program’s transformative potential, highlighting how this infusion of resources enables researchers to dissect the causal neural mechanisms driving bipolar disorder. “These new projects offer a pivotal opportunity to explore neural circuits and translate that knowledge into innovative treatment approaches,” Dr. Altimus remarked, stressing the importance of collaboration and data sharing in accelerating advancements that could fundamentally redefine patient care paradigms. This initiative signals a shift from symptomatic treatment toward precision medicine grounded in neural circuit biology.

Since its inception, BD² has channeled over $106 million into multifaceted research endeavors, fostering an integrative ecosystem committed to cross-disciplinary collaboration and open data exchange. The new grants focus on leveraging state-of-the-art neuromodulation methodologies such as deep brain stimulation, transcranial magnetic stimulation, and precision functional mapping tools. Through these techniques, scientists aspire to not only observe but actively manipulate brain circuits in real-time, aiming to pinpoint pathophysiological signatures of bipolar disorder and translate these discoveries into tangible clinical strategies.

One of the most innovative projects is led by Dr. Ignacio Saez at the Icahn School of Medicine, who is advancing efforts to chronically record human brain activity in individuals with bipolar disorder. By meticulously cataloging fluctuations in neural network dynamics concomitant with mood state changes, Dr. Saez’s team aims to build a comprehensive neural signature of mood switching. This endeavor integrates chronic electrophysiological recording with granular clinical phenotyping, representing a novel approach to correlating specific circuit-level disruptions with bipolar symptomatology, potentially guiding the future development of targeted neuromodulatory therapies.

Meanwhile, Dr. Michael Fox and his team at Mass General Brigham’s Center for Brain Circuit Therapeutics take a distinctive approach that seeks to map bipolar disorder symptoms onto discrete brain regions. They are employing a multifaceted investigative strategy that analyzes psychiatric symptom variation through studies of patients with localized brain lesions, postmortem brain tissue, and those undergoing focal brain stimulation. By dissecting symptomatology on the level of brain circuits, this research promises to illuminate causal pathways and identify therapeutic targets with unprecedented precision, potentially revolutionizing how bipolar disorder is understood and treated.

Early career researcher Dr. Charles Lynch at Weill Cornell Medicine applies precision neuroimaging and neuromodulation to chart the neural substrates of mood regulation. His team endeavors to delineate the precise neural circuitry responsible for mood instability—a core feature of bipolar disorder—by comparing brain states across different mood episodes. Through manipulating these circuits experimentally, Dr. Lynch hopes to distinguish causal relationships from mere correlates, thereby identifying specialized targets for interventions designed to stabilize mood fluctuations in affected individuals.

At the University of Minnesota, Dr. Ziad Nahas leads a pioneering project testing a novel, personalized brain stimulation technique previously employed to enhance cognitive and mood functions in unipolar depression. Through the integration of precision functional brain mapping, his group seeks to elucidate the neural underpinnings of mood switching unique to bipolar disorder. By calibrating stimulation parameters to individual neural signatures, this approach aspires to tailor treatments that can optimize therapeutic outcomes and minimize side effects, opening new pathways for personalized psychiatry.

This wave of research funding not only advances foundational knowledge of bipolar disorder but also exemplifies a broader paradigm shift toward open science and collaborative innovation in psychiatric research. BD²’s integrated platforms, including the Discovery Grants program, Brain Omics initiatives, and genetics platforms, facilitate an environment where data, methodologies, and insights flow freely between researchers worldwide. This model accelerates hypothesis testing and validation, breaking down traditional silos that have historically hampered progress in understanding complex psychiatric illnesses.

The forthcoming fourth round of funding announced by BD² continues this momentum, inviting new teams to propose projects that probe the genetic, molecular, cellular, circuit, and behavioral dimensions of bipolar disorder. These upcoming initiatives hold promise for unearthing multilayered mechanisms that underlie this enigmatic disorder, with the potential to drive innovative diagnostics and precision therapies. The holistic approach embraced by BD² exemplifies a commitment to exhausting all biological scales to capture the heterogeneity and complexity intrinsic to bipolar disorder.

Bipolar disorder, characterized by dramatic shifts in mood, energy, and function, has long posed a challenge for psychiatry due to its elusive biological underpinnings. Many current treatments remain symptomatic and nonspecific, underscoring an urgent need for mechanistic research capable of informing the development of more refined interventions. Through its comprehensive and collaborative funding approach, BD² is fueling a paradigmatic transformation, fostering research that integrates advanced neurotechnologies with clinical expertise to bridge this critical gap.

By fostering such ambitious and interwoven research trajectories, BD² aspires to dramatically shorten the timeline from scientific discovery to clinical application, thereby touching the lives of tens of millions worldwide affected by bipolar disorder. This ambitious vision embodies a commitment not only to scientific excellence but also to improving quality of life by enabling individuals with bipolar disorder to thrive, moving beyond mere symptom management toward sustained wellness and function.

Collectively, these efforts herald a new era in bipolar disorder research—one defined by neurocircuitry precision, collaborative openness, and translational impact. As these neuromodulation-focused projects unfold, they pave the way for a future where bipolar disorder can be understood in mechanistic detail and treated with tailored brain-based therapies, transforming care and outcomes for millions globally.

Subject of Research: Neural circuit mechanisms and neuromodulation in bipolar disorder
Article Title: BD² Launches $18 Million Neuromodulation-Focused Initiative to Decode Bipolar Disorder Brain Circuits
News Publication Date: Not specified
Web References:

• https://www.bipolardiscoveries.org/our-work/discovery-research/
• https://www.bipolardiscoveries.org/2025/09/bd2-announces-new-funding-opportunities-focused-on-biology-of-bipolar-disorder/
  Keywords: Bipolar disorder, neuromodulation, neural circuits, brain stimulation, mood regulation, neuroimaging, electrophysiology, precision psychiatry, collaborative research, neurobiology

Spatial omics, an area marking a paradigm shift in tissue analysis, enables scientists to map RNA transcripts and protein distributions within intact tissues. This multidimensional insight into cellular organization and interaction offers crucial clues to the biological architecture underpinning health and disease, fueling discoveries in oncology, neurodegeneration, and immunology. However, the vast complexity and heterogeneity intrinsic to spatial omics data have created substantial barriers to effective analysis, often requiring the use of fragmented, multi-package computational tools that impede seamless integration and interpretation.

Recognizing this bottleneck, the team led by Professors Guo-Cheng Yuan and Ruben Dries designed Giotto Suite as an all-encompassing ecosystem integrated within R, a versatile programming environment favored by biostatisticians and computational biologists. The platform’s core strength lies in its technology-agnostic approach, accommodating spatial datasets from diverse platforms regardless of scale or measurement type. This adaptability allows researchers to tailor their analytical workflow around their specific experimental setups and scientific questions, rather than being constrained by software limitations.

One of Giotto Suite’s key technical innovations is its modular architecture, which combines the end-to-end steps of a spatial omics analysis pipeline into a unified framework. From raw data preprocessing to advanced spatial visualization and integration of multi-modal data, each module is crafted to maintain interoperability yet functions cohesively to streamline complex workflows. This integration mitigates the common issue of error propagation and compatibility challenges encountered when piecing together disparate tools for spatial data analysis.

Beyond simplified data handling, Giotto Suite incorporates scalable computational algorithms designed to manage the ever-increasing size and resolution of spatial datasets. As spatial technologies progress towards single-cell and subcellular resolution with simultaneous multi-omics readouts, this scalability ensures that researchers can analyze their data without compromising speed or accuracy. Advanced spatial statistics embedded within Giotto offer novel ways to characterize cellular neighborhoods and molecular gradients, crucial for understanding tissue microenvironments.

The software’s flexible entry points represent another significant leap forward. Users can commence their analyses from varied stages: raw data inputs, partially processed datasets, or integrated multi-modal outputs. This flexibility suits a wide array of research workflows, promoting inclusivity for new users while providing customization power for experienced bioinformaticians. Giotto Suite also supports cross-platform data harmonization, enabling meta-analyses that combine datasets from different spatial omics technologies, a capability vital for large consortium studies and reproducibility efforts.

Despite its robust feature set, the creators acknowledge that the initial release encompasses only a portion of spatial analytical methodologies required by the field’s full spectrum of research queries. They emphasize Giotto Suite’s evolutionary design, inviting community contributions and user feedback. Committed to maintaining an open-source ethos, the team plans continuous expansion with enhanced interoperability to third-party tools, improved visualization capacities, and comprehensive training resources to accelerate adoption.

The development of Giotto Suite was generously supported by notable funding bodies including the Chan Zuckerberg Initiative’s Essential Open Source Software for Science Program, the Alex’s Lemonade Stand Foundation’s Crazy 8 Initiative, and several NIH grants. This broad financial backing reflects the scientific community’s recognition of spatial omics as a cornerstone of future biomedical research and the pressing need for accessible analytical infrastructure.

Looking ahead, Yuan, Dries, and their collaborators intend to directly apply Giotto Suite in their ongoing investigations into cancer biology and neurodegenerative diseases. They anticipate that the platform will expedite the identification of spatial molecular signatures and uncover new cellular phenotypes, ultimately informing targeted therapies and diagnostics. Their commitment to iterative refinement ensures that Giotto Suite will evolve in tandem with emerging spatial technologies and computational innovations.

Giotto Suite’s release marks a pivotal moment in spatial omics research—transforming abundant yet complex spatial data into actionable biological insights. As spatial resolution and multi-omic depth accelerate, tools like Giotto Suite will be indispensable, democratizing access to spatial data analytics and catalyzing breakthroughs across biomedical disciplines. The availability of this open-source platform invites a new era where scientists can seamlessly decode the spatial intricacies of life at molecular and cellular scales.

Researchers interested in exploring Giotto Suite can access the software freely through http://giottosuite.com, fostering broad engagement from the global scientific community. Such open dissemination amplifies collaborative opportunities and accelerates the collective endeavor to unravel spatial biology’s mysteries. Giotto Suite stands as a beacon of innovation, promising to reshape our understanding of tissue biology, disease mechanisms, and ultimately, human health.

Subject of Research: Human tissue samples
Article Title: Giotto Suite: a multi-scale and technology-agnostic spatial multi-omics analysis ecosystem
News Publication Date: 1-Oct-2025
Web References: http://giottosuite.com; http://dx.doi.org/10.1038/s41592-025-02817-w
References: Chen, Chávez-Fuentes, et al., Nature Methods, DOI: 10.1038/s41592-025-02817-w
Image Credits: Chen, Chávez-Fuentes, et al., Nature Methods
Keywords: Genomics

AEquity stands at the forefront of efforts to ensure that AI tools are equitable and accurate. In its quest to address bias, the research team rigorously tested AEquity on a diverse array of health data, emphasizing its versatility across various domains, including medical imaging and patient records. Notably, the tool’s broad application was seen during evaluations of a significant public health dataset: the National Health and Nutrition Examination Survey. The capability of AEquity to detect both overt and subtle biases across these datasets signals a paradigm shift in how researchers and healthcare developers can approach data integrity and trustworthiness.

As AI tools become increasingly influential in decisions concerning diagnostic processes and cost predictions, the underlying datasets’ integrity is paramount. Historical representations within data can often skew the performance of machine-learning systems, particularly if certain demographic groups are underrepresented. This leads to a cycle where inaccuracies are perpetuated, resulting in missed diagnoses or even harmful outcomes for marginalized populations. The researchers recognized this critical issue and emphasized the necessity of ensuring that AI systems do not become vehicles for amplifying discrepancies in healthcare delivery.

Dr. Faris Gulamali, the lead author of the study, articulated the team’s mission with AEquity: to create a pragmatic solution for health systems and developers that aids in recognizing and correcting bias within their datasets. The vision is clear—this tool aims to ensure that AI applications in medicine are equitable and beneficial for all demographics, not just those predominantly represented in existing datasets. Dr. Gulamali’s insights underscore a growing recognition within the field that technical tools alone are insufficient; broader systemic changes in data collection and interpretation are equally vital for fostering healthcare equity.

One of the standout features of AEquity is its adaptability across various machine-learning models, ranging from simpler algorithms to sophisticated systems akin to those that govern large language models. This adaptability is not merely a technical convenience; it speaks to the urgent need for tools capable of functioning in diverse scenarios, whether handling small datasets or large, complex ones. AEquity assesses both the input data—such as lab results and medical images—and the algorithmic outputs, which can include prognosed diagnoses and risk assessments. This comprehensive approach positions AEquity as a potentially transformative resource for various stakeholders in the healthcare landscape.

As the research team detailed, AEquity does not serve merely as a diagnostic tool but as a comprehensive framework that could assist developers, researchers, and regulatory bodies throughout the AI development lifecycle. Its utility spans from initial algorithm conception to pre-deployment audits, exemplifying the tool’s important role in enhancing fairness in healthcare-driven artificial intelligence. AEquity is not just a step forward; it is a call to action for all involved in health informatics and AI development.

Senior corresponding author Dr. Girish N. Nadkarni emphasized that while tools like AEquity are crucial in addressing bias in AI, they represent only a fraction of the solution needed. He advocates for a broader scope of change that encompasses methods of data collection, interpretation, and the overall application of technological systems in healthcare. The future of equitable health technology hinges on improving foundational data integrity while implementing advanced tools and methodologies like AEquity.

Another key figure in this study, Dr. David L. Reich, who serves as the Chief Clinical Officer at Mount Sinai, echoed the sentiment that identifying and correcting biases at the dataset level is essential to advancing healthcare equity. He highlighted that this proactive approach helps establish community trust in AI technologies while enhancing patient outcomes for diverse groups. This emphasis on ethical AI in healthcare reflects a shift towards grounding technological innovations in fairness and equity, thereby transforming how healthcare services are delivered and perceived.

The significance of AEquity lies not only in its technical capabilities but also in its potential to educate and shift perspectives within the healthcare community regarding AI’s role. As systems such as AEquity gain traction, they embody a movement toward conscious decision-making in healthcare tech—ensuring that advancements serve all patients equitably. The aim is to cultivate an environment where AI systems contribute positively and constructively to health outcomes across various communities, paving the way for a more equitable health infrastructure system.

The research, titled “Detecting, Characterizing, and Mitigating Implicit and Explicit Racial Biases in Health Care Datasets With Subgroup Learnability: Algorithm Development and Validation Study,” encompasses a collaborative effort from prominent figures in the field of health informatics and AI research. This collaborative ethos underlines the importance of multifaceted approaches to tackling complex issues within healthcare technology and emphasizes the need for diverse perspectives and expertise in driving innovation.

In conclusion, the development of AEquity represents a significant milestone in the ongoing journey toward integrating artificial intelligence effectively and ethically into healthcare practice. This tool not only promises to unearth biases within datasets but also serves as a catalyst for broader changes regarding how healthcare data is approached. As healthcare systems worldwide strive to harness the potential of AI while safeguarding against inequities, initiatives like AEquity illuminate a path forward—one that prioritizes fairness, accuracy, and, ultimately, enhanced patient care. The collaborative spirit driving this research exemplifies the future direction of AI in healthcare: inclusivity, adaptability, and a relentless commitment to enhance the welfare of all patients.

Subject of Research: People
Article Title: Detecting, Characterizing, and Mitigating Implicit and Explicit Racial Biases in Health Care Datasets With Subgroup Learnability: Algorithm Development and Validation
News Publication Date: 4-Sep-2025
Web References: Journal of Medical Internet Research
References: National Institutes of Health, National Center for Advancing Translational Sciences
Image Credits: Gulamali, et al., Journal of Medical Internet Research

Keywords

Artificial intelligence, healthcare, data bias, machine learning, equitable AI, health algorithms

Triple-negative breast cancer, characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, accounts for roughly 10 to 15 percent of breast cancer diagnoses. Its aggressive nature and limited responsiveness to hormonal or HER2-targeted therapies render treatment options notably scarce and oftentimes ineffectual. This stark clinical reality underscores the urgent necessity of novel therapeutic strategies that can disrupt the molecular machinery driving TNBC progression.

Central to this study’s rationale is the role of the PTEN tumor suppressor gene, frequently lost or mutated in TNBC tumors. PTEN functions as a critical guardian of cellular homeostasis by restraining aberrant cell proliferation. Its absence unleashes unchecked activation of the mTOR signaling pathway—a pivotal cellular “growth switch” that fosters tumor expansion and metastatic potential. Everolimus, an mTOR inhibitor already approved for other malignancies, offers a mechanistic counterpunch by dampening this hyperactive pathway, thereby restraining cancer cell growth.

The trial enrolled patients with advanced TNBC who had undergone up to three prior lines of therapy, reflecting a heavily pretreated population often devoid of effective options. Participants were randomly assigned to receive either carboplatin alone, a platinum-based chemotherapeutic DNA-damaging agent with broad antitumor activity, or a combination of carboplatin plus everolimus. The results were compelling: those receiving the combination exhibited a remarkable 52 percent reduction in the risk of disease progression or death compared to those treated with carboplatin monotherapy.

Importantly, beyond efficacy, the combination regimen maintained a manageable safety profile. No unexpected adverse events emerged, and treatment tolerability appeared consistent with known profiles of the individual agents. This balance of enhanced therapeutic benefit and tolerability holds immense clinical promise, addressing a critical unmet need for patients with metastatic TNBC.

Dr. Amy Tiersten, Professor of Medicine in Hematology and Medical Oncology and senior author of the study, emphasized that the findings “suggest a new treatment paradigm that could potentially improve outcomes for patients suffering from this aggressive breast cancer subtype.” She further noted the imperative for subsequent phase 3 trials to corroborate these results, laying the groundwork for regulatory approval and clinical adoption.

Delving deeper into molecular oncology, TNBC’s lack of hormone receptors precludes use of targeted endocrine therapies, rendering chemotherapy the mainstay treatment despite its limited efficacy and considerable toxicity. The discovery that mTOR inhibition can potentiate chemotherapy represents a refined therapeutic tactic aimed at hindering tumor cell proliferation at a signaling level while leveraging DNA damage via carboplatin molecules.

The findings resonate within the broader landscape of precision oncology, where unraveling tumor-specific vulnerabilities facilitates tailored treatment combinations that maximize efficacy while minimizing collateral damage. The integration of everolimus confronts the aberrant signaling cascade propelling tumor growth, exemplifying how targeted agents can resensitize resistant tumors to cytotoxic therapies.

Experts underscore that the study’s patient cohort, characterized by prior treatment resistance and advanced disease, typifies a population in dire need of innovation. That substantial clinical benefit was achieved in this context advances hope for altering the dismal prognosis typically associated with metastatic TNBC, which historically manifests median survival measured in months.

Future investigations will need to elucidate biomarkers predictive of response to everolimus-carboplatin therapy to enable optimal patient selection. Molecular profiling might identify specific genetic or proteomic signatures corresponding to heightened reliance on mTOR signaling, thereby refining therapeutic indices and sparing non-responders from unnecessary toxicity.

The study’s underpinning translational research highlights the synergy between basic scientific insights—identifying PTEN loss and mTOR pathway activation—and clinical application through rational drug combination designs. This bench-to-bedside approach exemplifies the cutting-edge paradigm necessary to confront formidable cancers effectively.

While additional larger-scale phase 3 studies are paramount to confirm these promising phase 2 results, the current data inject a dose of optimism for patients and clinicians alike. Should efficacy be validated, carboplatin coupled with everolimus may soon expand the armamentarium against TNBC, potentially shifting treatment standards from empirical chemotherapy to more nuanced, pathway-informed regimens.

Furthermore, the role of pharmaceutical partners such as Novartis in providing investigational drugs exemplifies the collaborative ecosystem essential for advancing oncology therapeutics from concept to clinic, underscoring the intersection of academic innovation and industry support.

As research continues to unfurl the complexities of TNBC biology and resistance mechanisms, studies like this propel the field closer to tailored, effective, and durable treatment solutions. The Icahn School of Medicine at Mount Sinai thus contributes a pivotal chapter in the evolving narrative aimed at conquering one of the most vexing subtypes of breast cancer.

Subject of Research: People

Article Title: (Not provided)

News Publication Date: August 20, 2025

Web References:

• https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html
• https://link.springer.com/article/10.1007/s10549-025-07802-7
• http://dx.doi.org/10.1007/s10549-025-07802-7
• https://physicians.mountsinai.org/videos/ramon-parsons-md-phd-explains-pten-and-cancer

References:

• Breast Cancer Research and Treatment, DOI: 10.1007/s10549-025-07802-7

Keywords: Breast cancer, Cancer treatments

The research team embarked on a meticulous evaluation of popular large language models (LLMs) by crafting controlled experimental scenarios featuring entirely fictional medical terms—fake diseases, symptoms, and diagnostic tests. These fabricated patient cases were designed to assess if AI chatbots would blindly accept and elaborate on erroneous information embedded within queries. Initial results were troubling: without intervention, the chatbots not only regurgitated the false data but often augmented it with confident, detailed explanations about these invented conditions, effectively demonstrating a hallmark behavior known as “hallucination,” where models produce convincing yet entirely fabricated content.

Crucially, the investigators identified a simple yet powerful mitigation strategy. By appending a concise cautionary prompt to the AI input—alerting the system that the provided information might be inaccurate—they observed a marked decrease in the frequency and severity of hallucinated responses. This modification effectively halved the incidence of erroneous elaborations, suggesting that prompt engineering and built-in safety warnings can serve as practical countermeasures to reduce misinformation propagation in AI-enabled healthcare applications.

Mahmud Omar, MD, the lead author and an independent consultant collaborating on this study, emphasized the ease with which these systems can be derailed. “Our experiments showed that AI chatbots are highly susceptible to being misled by false medical details—whether introduced accidentally or deliberately. The danger lies not only in parroting misinformation but also in crafting detailed, plausible narratives around these untrue facts,” he explained. Omar noted that the intervention of a simple one-line warning in the prompt dramatically diminished such hazardous behaviors, underscoring that even incremental design changes can have outsized impacts on safety.

The study’s methodology involved a two-pronged approach. In the first phase, chatbots were prompted with fabricated clinical vignettes devoid of any safety instructions, allowing researchers to observe natural responses. In the subsequent phase, a brief disclaimer was embedded within the prompt, cautioning the model about potential inaccuracies in the input data. The comparative analysis clearly demonstrated that the presence of the warning significantly curtailed hallucination rates, reinforcing the concept that proactive prompt design is an indispensable component of responsible AI deployment in medical contexts.

Eyal Klang, MD, Chief of Generative AI in the Windreich Department of Artificial Intelligence and Human Health at Mount Sinai and co-corresponding senior author, highlighted the gravity of their findings. “Even a single fabricated term injected into a medical question can trigger the model to generate an authoritative-sounding but entirely fictional medical explanation. However, our results also provide a roadmap for safer AI use: carefully timed safety prompts can meaningfully mitigate those errors, pointing to a future where AI can augment clinical workflows without compromising accuracy,” he stated.

Beyond immediate practical implications, the researchers intend to extend their “fake-term” testing paradigm to real-world datasets, involving de-identified patient records. This next phase aims to stress-test AI systems against misinformation within authentic clinical contexts, allowing for further refinement of safety prompts and integration of retrieval-based tools that may cross-validate the chatbot’s outputs against trustworthy medical knowledge bases. Their iterative validation approach aspires to create robust mechanisms that prevent AI hallucinations from influencing patient care decisions.

Girish N. Nadkarni, MD, MPH, Chair of the Windreich Department of Artificial Intelligence and Human Health and co-corresponding senior author, underscored the broader significance of this research. “Our study shines a spotlight on a blind spot within current AI models—their inadequate handling of false medical information, which can generate dangerously misleading responses. The solution lies not in abandoning AI but in engineering systems designed to recognize questionable input, respond with appropriate caution, and preserve essential human oversight,” he reflected. Nadkarni emphasized that deliberate safety measures and thoughtful AI prompt design are critical levers to unlocking the potential of AI in healthcare while mitigating risks.

The pressing issues revealed by this investigation resonate widely across the rapidly expanding intersection of AI and medicine. As clinicians and patients increasingly adopt AI tools for decision support, the need for transparent, reliable, and safe systems is paramount. Hallucinations—defined as confident AI fabrications—could lead not only to diagnostic errors but also to erosion of trust in technology-assisted medicine. This study’s findings prompt a call for regulatory frameworks, stringent validation protocols, and responsible AI integration practices that prioritize patient safety above all.

Technically, this research also advances our understanding of the cognitive vulnerabilities inherent in large language models. These transformer-based architectures rely heavily on patterns learned from expansive datasets rather than grounded medical fact verification, making them inherently vulnerable to propagating misinformation when presented deceptively. The study’s insight that a relatively minimal prompt addition can effectively curb hallucination frequency suggests that the problem can be partially addressed at the interface between human input and AI generation, rather than requiring entirely new model architectures.

In addition to safety prompt engineering, the study hints at the importance of developing AI systems capable of uncertainty quantification and fact-checking. Future models may incorporate retrieval augmented generation (RAG) techniques, linking generated responses to verified medical literature or electronic health records in real-time to validate outputs. Such approaches, combined with real-time human intervention, could transform AI chatbots from mere language predictors into reliable clinical assistants supporting complex decision making.

Mount Sinai’s Windreich Department of Artificial Intelligence and Human Health, under the leadership of Drs. Nadkarni and Klang, is at the forefront of pioneering responsible AI applications in biomedical contexts. This study not only exemplifies their commitment to ethical AI but also provides a foundational framework for other institutions seeking to evaluate and enhance the safety of AI-driven clinical decision tools. Their continued collaboration with the Hasso Plattner Institute for Digital Health underscores a multidisciplinary approach that bridges computational science, engineering, and clinical medicine.

As artificial intelligence continues to permeate healthcare, studies like this expose the critical challenges posed by AI hallucinations and misinformation. Nevertheless, the promising results around simple safety prompts reflect an optimistic path forward where AI tools can be refined and rigorously tested to meet the high standards essential for clinical reliability. The balance between innovation and caution articulated by the Mount Sinai team paves the way for transformative yet responsible AI advancements that ultimately benefit patient outcomes and the future of medicine.

Subject of Research: Evaluation of misinformation propagation and hallucination tendencies in AI chatbots for clinical decision support, and the effectiveness of safety prompt interventions.

Article Title: Large Language Models Demonstrate Widespread Hallucinations for Clinical Decision Support: A Multiple Model Assurance Analysis

News Publication Date: August 6, 2025

Web References:
https://dx.doi.org/10.1038/s43856-025-01021-3
https://ai.mssm.edu/

References:

• Omar, M., Sorin, V., Collins, J.D., Reich, D., Freeman, R., Charney, A., Gavin, N., Stump, L., Bragazzi, N.L., Nadkarni, G.N., & Klang, E. (2025). Large Language Models Demonstrate Widespread Hallucinations for Clinical Decision Support: A Multiple Model Assurance Analysis. Communications Medicine, August 2, 2025.

Keywords:
Machine Learning, Artificial Intelligence, Large Language Models, AI Hallucinations, Clinical Decision Support, Medical Misinformation, Prompt Engineering, AI Safety, Digital Health, Biomedical Informatics

Traditional antidepressant treatments primarily modulate monoaminergic systems such as serotonin and norepinephrine. However, nearly half of all patients with major depressive disorder fail to respond to these first-line interventions, often continuing to suffer from chronic symptoms including debilitating anhedonia. This therapeutic gap underscores the urgent need for novel mechanisms of action that more directly influence the underlying neurobiological substrates of depression. The Potassium Voltage-Gated Channel Subfamily Q member (KCNQ) emerges from these investigations as a promising candidate, with its modulation presenting a fundamentally different pathway through which neuronal excitability and circuit-level dysfunctions can be corrected.

The pivotal drug examined in these studies, ezogabine (also known as retigabine), originally approved by the U.S. Food and Drug Administration (FDA) in 2011 as an anticonvulsant for partial-onset seizures, acts as an opener of KCNQ potassium channels. Its role in epilepsy centers on stabilizing hyperactive neurons by enhancing potassium conductance, thereby dampening aberrant electrical activity. Building on preclinical data from murine models of depression, which demonstrated antidepressant-like effects of KCNQ activation, the Mount Sinai team spearheaded human trials to explore ezogabine’s capacity to modulate mood disorders.

The initial clinical trial, published in the American Journal of Psychiatry in 2021, marked the first direct assessment of ezogabine in depressed human subjects. Patients treated with ezogabine exhibited statistically significant improvements not only in depressive symptoms but also in hedonic capacity. These results spurred deeper neuroimaging studies to dissect the drug’s mechanistic impact on neural circuits central to reward processing and mood regulation.

The first detailed study, appearing in Molecular Psychiatry, conducted functional magnetic resonance imaging (fMRI) assessments focusing on the ventral tegmental area (VTA)—a midbrain structure renowned for its role in dopaminergic signaling related to motivation and reward. The VTA is notoriously implicated in anhedonia due to dysregulated dopamine release, which impairs the brain’s reward system and diminishes the experience of pleasure. The fMRI findings revealed that ezogabine administration normalized hyperactivity within the VTA among individuals exhibiting both depression and anhedonia, indicating that KCNQ channel modulators can recalibrate dysfunctional activity patterns in crucial motivational circuits.

Laurel S. Morris, PhD, the study’s first author and an Adjunct Professor of Psychiatry at Icahn, emphasizes that this normalization of VTA function translates into potential clinical benefits: “Because a significant subset of patients with depression do not achieve symptomatic relief through existing therapies targeting traditional neurotransmitters, drugs like ezogabine that specifically restore the balance of brain reward circuitry might be the key to enhancing treatment efficacy and improving overall patient outcomes.”

The second study, published in Biological Psychiatry, complements these findings by illustrating alterations in the broader brain network connectivity patterns under the influence of ezogabine. This research pinpointed reductions in connectivity between key reward regions—such as the nucleus accumbens and other dopaminergic targets—and the posterior cingulate cortex (PCC), a hub implicated in internally focused thought processes, including rumination and negative emotional states. Patients who experienced greater clinical improvements demonstrated more considerable decreases in this connectivity, suggesting that ezogabine’s therapeutic actions may include modulating the interplay between reward and default-mode networks that underlie maladaptive cognitive patterns in depression.

Together, these studies propose a model in which KCNQ channel openers like ezogabine function by dampening the pathological coupling between regions governing reward experience and those associated with self-referential and negative affective processing. This targeted modulation holds promise for interrupting the vicious cycles of negative thought and emotional dysregulation that fuel depressive illness, laying the groundwork for a new class of antidepressants with distinct mechanistic profiles.

The identification of KCNQ channels as a nexus in depression’s neurobiology also opens exciting avenues for drug discovery. Unlike conventional antidepressants that indirectly influence neuronal excitability, KCNQ modulators offer a more direct approach to regulating membrane potentials and neuronal firing rates in reward pathways. This alternative pharmacological strategy could overcome the limitations of slow onset and insufficient efficacy seen with current treatments.

James Murrough, MD, PhD, Director of the Depression and Anxiety Center for Discovery and Treatment at Mount Sinai and senior author of the studies, remarks on the translational potential: “Understanding how to manipulate ion channel function to alter circuit dynamics not only enhances our grasp of depression’s underpinnings but also heralds the arrival of precision-targeted therapies that could change patients’ lives.”

While the promise of ezogabine is undeniable, Dr. Murrough and colleagues caution that the current findings are preliminary and derived from relatively small cohorts. Rigorous, larger-scale clinical trials are essential to verify efficacy and safety, explore dose optimization, and clarify the scope of clinical populations that would benefit most. Additionally, the side effect profiles unique to KCNQ channel modulators will require careful evaluation.

Intriguingly, Dr. Murrough holds a pending patent related to ezogabine and similar KCNQ channel openers for depression, emphasizing the innovative and translational nature of this research. This patent signals the potential commercialization and eventual clinical integration of these compounds if future trials prove successful.

Beyond clinical implications, these insights enrich our understanding of depression as a disorder of circuit and network dysfunction, moving the field away from monoamine-centric models to embrace the complexity of neurobiological substrates involving ion channel physiology. Such a shift aligns with broader neuroscientific trends emphasizing the role of neuronal excitability and connectivity in psychiatric illnesses.

Mount Sinai Health System, a leading academic medical center and research institution, underpins these efforts with extensive interdisciplinary resources, including advanced imaging technologies and clinical trial infrastructures. This integration facilitates rapid bench-to-bedside translation, enhancing the likelihood that novel discoveries like the KCNQ channel mechanism will culminate in tangible benefits for patients.

As depression continues to impose substantial global health burdens, affecting millions worldwide, innovative treatments remain a critical unmet need. The elucidation of potassium channel modulation as a therapeutic strategy not only injects fresh hope but also exemplifies the power of precision neuroscience to revolutionize mental health care.

In conclusion, the collaborative work at Mount Sinai marks a vital step toward a future where depression therapies are tailored to correct specific neurophysiological abnormalities rather than broadly altering neurotransmitter levels. By unlocking the potential of KCNQ channels, scientists may usher in a new era of antidepressant development, offering relief to those for whom current treatments fall short.

Subject of Research: People

Article Title: Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia

News Publication Date: 25-Mar-2025

Web References:

• https://dx.doi.org/10.1038/s41380-025-02957-7
• https://psychiatryonline.org/doi/10.1176/appi.ajp.2020.20050653
• https://www.biologicalpsychiatryjournal.com/article/S0006-3223(25)01011-X/abstract

Image Credits: Mount Sinai Health System

Keywords: Depression, Potassium channels, Ion channels, Neuroscience

The researchers focused on a phenomenon called digenic inheritance, where two genes collectively interact to influence the risk of developing a particular disease. This duo of genetic factors threatens to reframe the discourse surrounding the genetic underpinnings of congenital heart disease, highlighting the intricate and multifaceted nature of its causation. Co-corresponding senior author Dr. Yuval Itan, an Associate Professor of Genetics and Genomic Sciences, expressed the significance of their findings. He described the potential implications for improving diagnostic precision and facilitating personalized treatment approaches.

Despite years of advancements in medical genetics, a significant number of congenital heart disease cases remain unexplained, with over half still lacking a definitive molecular diagnosis. The team’s analysis of trio exome sequencing data from both affected and unaffected children was pivotal in unraveling the complexity of digenic interactions. This innovative methodology allowed researchers to identify ten gene pairs that could play essential roles in the development of CHD, shedding light on previously hidden genetic liabilities.

In the realm of genetic research, understanding that genetic interactions may play a crucial role beyond single-gene mutations is revolutionary. First author Dr. Meltem Ece Kars, a postdoctoral fellow, emphasized the importance of their work, stating that unearthing these interactions could significantly enhance diagnostic yields in clinical genetics. They propose that as the technologies behind genetic testing continue to evolve, the integration of digenic models into standard practice could bring newfound clarity to patients and clinicians alike.

The research team adopted a robust computational framework to identify gene pairs that could jointly contribute to the risk of congenital heart disease. This new approach could serve as a powerful tool for future genetic studies focused on complex diseases. Researchers believe it may lead to deeper insights into the genetic etiology of various disorders, pushing forward the frontiers of genomic research that have remained unexplored due to the complexities inherent in multifactorial conditions.

Looking to the future, Dr. Itan voiced ambitions to extend their digenic approach beyond congenital heart disease to other disorders where the genetic basis is not fully understood. This outward reach aims to tackle instances of missing heritability in multifactorial diseases, potentially unveiling new pathways to elucidate genetic contributions to diseases that have been shrouded in ambiguity.

Understanding the broader implications of their findings, the research team anticipates that this work will not only refine genetic diagnoses for congenital heart disease but also improve risk assessments and genetic counseling for families affected by these conditions. By focusing on the interactive nature of genes rather than isolating them, they hope to create a framework for more effective therapies tailored to the individual genetic profiles of patients.

The study also emphasizes the importance of collaboration within scientific communities. With contributions from various experts in genetics, the research enriches the collective understanding of human genetics. This multi-disciplinary involvement serves as a reminder of the collaborative nature of scientific inquiry, where diverse expertise converges to tackle existing enigmas in medicine.

Acknowledging the continued support of institutions such as the National Heart, Lung, and Blood Institute of the National Institutes of Health, Dr. Kars pointed out the vital role of funding in advancing scientific research. The resilience and commitment to solving pressing health issues showcased by the funding bodies not only facilitate the research process but also inspire future explorations into genetic factors associated with various complex diseases.

This study is poised at the confluence of genetic research and clinical application, embodying the ideals of translational medicine. As clinicians and geneticists increasingly recognize the significance of understanding patient-specific genetic landscapes, there is a growing anticipation that the rigorous methodologies unveiled in this research might lead to improved therapies, enhancing both the diagnosis and treatment of congenital heart disease.

The revelations presented by this study serve as an impetus for further inquiries into genetic frameworks underlying diseases broadly defined as complex. The promise that digenic models hold for illuminating the interactions of multiple risk factors in disease development resonates not only within the realm of genetics but across various medical disciplines. This burgeoning field opens the door to comprehensive strategies aimed at combating congenital conditions that hinder the health of countless individuals.

In light of these promising developments, the scientific community is eager to build upon this foundation. The potential impact on not only congenital heart diseases, but broader genetic conditions, may redefine our diagnostic strategies and therapeutic interventions, thus improving the quality of life for numerous patients globally.

As this groundbreaking research solidifies its place within the narrative of genetic medicine, its authors encourage a dialogue on the necessity for innovation within genetic studies. By appealing to a greater understanding of the intricate web formed by genetic variant interactions, the hope is to inspire collaborative efforts that can unveil further complexities in human genetics, propelling the discipline toward new frontiers in healthcare.

Moving forward, the conversations ignited by this study may provide fertile ground for future research initiatives aimed at enhancing our grasp of genetic interactions in disease mechanisms. Such work will undoubtedly shape the future landscape of clinical genetics, driving efforts toward a more nuanced understanding of health and disease that could benefit generations to come.

Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:

Keywords: